Zurcher Kantonalbank Zurich Cantonalbank Sells 383,550 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Zurcher Kantonalbank Zurich Cantonalbank trimmed its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 91.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 35,527 shares of the medical equipment provider's stock after selling 383,550 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank owned 0.05% of Lantheus worth $3,899,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of LNTH. Signaturefd LLC lifted its position in shares of Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock valued at $35,000 after buying an additional 92 shares during the last quarter. Silverberg Bernstein Capital Management LLC raised its stake in shares of Lantheus by 0.4% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider's stock valued at $1,834,000 after purchasing an additional 100 shares during the period. UMB Bank n.a. boosted its stake in Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after purchasing an additional 126 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Lantheus by 45.5% in the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock worth $51,000 after buying an additional 146 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its position in shares of Lantheus by 4.5% in the second quarter. Nisa Investment Advisors LLC now owns 6,643 shares of the medical equipment provider's stock valued at $533,000 after acquiring an additional 287 shares during the period. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Price Performance

LNTH stock traded down $1.07 during midday trading on Tuesday, hitting $88.51. The stock had a trading volume of 1,321,857 shares, compared to its average volume of 1,022,870. The firm has a market cap of $6.15 billion, a price-to-earnings ratio of 14.73 and a beta of 0.45. The business has a 50-day moving average of $100.90 and a two-hundred day moving average of $97.43. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on LNTH shares. JMP Securities reduced their price target on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating for the company in a research report on Thursday, November 7th. StockNews.com cut shares of Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. Redburn Atlantic assumed coverage on Lantheus in a research note on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price target for the company. Finally, Truist Financial reissued a "buy" rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Lantheus presently has a consensus rating of "Moderate Buy" and an average price target of $125.71.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.